Laffont's AI-to-Biotech Shift: CoreWeave Out, Moderna In
💡 Puntos Clave
A prominent tech investor is rotating from high-flying AI infrastructure to a beaten-down biotech with promising pipeline assets.
The Billionaire's Portfolio Reshuffle
Billionaire Philippe Laffont of Coatue Management, who oversees $39 billion in assets, made two significant moves in the fourth quarter. He completely exited his position in CoreWeave (CRWV), an AI infrastructure company that had been a major winner in his portfolio. The stock had climbed about 80% from its IPO through the end of 2025, representing over 2.2% of his holdings at its peak.
Simultaneously, Laffont initiated a new, albeit small, position in Moderna (MRNA), purchasing 200,000 shares. This new bet accounts for just 0.01% of his portfolio, indicating it's a starter position rather than a core holding. The move came just before Moderna's stock surged nearly 50% in January.
The trades represent a classic 'sell the winner, buy the potential turnaround' strategy. Laffont locked in substantial gains from CoreWeave, a stock that benefited from the massive AI boom, and redeployed a tiny portion of that capital into a biotech stock that had fallen on hard times. This activity was disclosed through a mandatory quarterly 13F filing.
It's worth noting that Laffont's largest holding remains Taiwan Semiconductor Manufacturing (TSM), which constitutes more than 6.5% of his portfolio. This suggests his overall faith in the technology sector remains strong, even as he adjusts specific holdings within it.
Reading the Tea Leaves on a Tech Titan's Moves
Laffont's decision to sell CoreWeave is significant because it suggests a top tech investor may believe the easy money has been made in certain AI infrastructure plays. While CoreWeave's business of renting AI compute capacity has seen triple-digit revenue growth, exiting a position after such a strong run can signal a belief that future upside may be limited or that valuation has become stretched.
His entry into Moderna, even as a small position, indicates he sees a compelling risk-reward opportunity in the beaten-down biotech. Moderna's stock had lost more than 70% over three years as demand for its COVID-19 vaccine waned, making it a classic 'fallen angel' story that can attract contrarian investors.
For Moderna, attracting a savvy tech investor like Laffont provides a vote of confidence in its strategic pivot. The company is shifting from a single-product focus to building a diversified portfolio, including a respiratory vaccine franchise and a promising pipeline in oncology and rare diseases. A phase 3 oncology candidate adds near-term catalysts.
The moves highlight a broader investment theme: rotation within high-growth sectors. Instead of abandoning tech entirely, Laffont is moving from a hot AI stock to a biotech that leverages technological innovation (mRNA platform). This suggests he still seeks growth but is hunting for it in undervalued areas with long-term potential.
For retail investors, this serves as a case study in portfolio management—taking profits on winners and selectively adding new ideas with asymmetric upside potential. However, the small size of the Moderna position reminds us that billionaires often test the waters cautiously before making bigger commitments.
Fuente: The Motley Fool
Análisis generado por el modelo cuantitativo de Bobby AI, revisado y editado por nuestro equipo de investigación. Esto no constituye asesoramiento financiero. Investigue por su cuenta antes de tomar decisiones de inversión.
Bobby Insight
Moderna presents an interesting speculative opportunity for long-term investors, but its small position size in Laffont's portfolio suggests starting small.
Laffont's track record in tech gives credibility to his biotech pick, and Moderna's deep pipeline offers multiple shots on goal. However, biotech investing carries high regulatory and clinical trial risks, making this suitable only for risk-tolerant portfolios.
¿Cómo Me Afecta?
